Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBT (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBT for 15 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 40.89% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.2 million, a 105.44% increase, with the full-year FY2025 number at $18.2 million, up 105.44% from a year prior.
  • EBT was $4.4 million for Q4 2025 at Niagen Bioscience, down from $4.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $7.5 million in Q4 2024 to a low of -$8.9 million in Q3 2021.
  • A 5-year average of -$1.2 million and a median of -$1.2 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 111.06% in 2021, then surged 25013.33% in 2025.
  • Niagen Bioscience's EBT stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114000.0 in 2023, then surged by 6464.91% to $7.5 million in 2024, then crashed by 40.89% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's EBT are $4.4 million (Q4 2025), $4.8 million (Q3 2025), and $3.7 million (Q2 2025).